Scleroderma

Pulmonary Function Tests May Underdiagnose Interstitial Lung Disease in Juvenile Systemic Sclerosis

Study authors determined the performance of pulmonary screening vs HRCT in detecting interstitial lung disease in juvenile SSc.

Gastrointestinal Transit Abnormalities Associated With Severe GI Symptoms in Scleroderma

Researchers evaluated the contribution of abnormal GI transit to systemic sclerosis Medsger GI severity scores and/or UCLA GIT 2.0 symptoms.

Assessing the Long-Term Safety and Efficacy of Tocilizumab in Systemic Sclerosis

The long-term safety and efficacy of tocilizumab in patients with systemic sclerosis were assessed in an open-label study.

Higher Neutrophil Count Linked to Mortality in Systemic Sclerosis-Related Interstitial Lung Disease

A higher neutrophil count predicted worse disease course and higher long-term mortality in patients with systemic sclerosis-related interstitial lung disease.

Iloprost Can Reverse Vascular Dysfunction in Scleroderma

Researchers evaluated the cellular mechanism of iloprost in reversing vascular dysfunction in scleroderma.

Elastography Ultrasound Feasible in Assessing Disease Activity in Pediatric-Onset Localized Scleroderma

Researchers determined the feasibility of elastography ultrasound in the assessment of pediatric-onset localized scleroderma.

Evaluating Novel Classifications for Systemic Sclerosis

Recent studies have evaluated new approaches to understand the heterogeneity of systemic sclerosis by optimizing disease classification.

Gene Expression in Patients With Severe Scleroderma May Predict Stem Cell Transplant Response

Researchers determined whether machine learning could predict stem cell transplant response in severe scleroderma.

Similar Outcomes for Ischemic Stroke Hospitalizations With and Without Systemic Sclerosis

Researchers compared the hospitalization outcomes of patients with ischemic stroke with and without a secondary diagnosis of systemic sclerosis.

Adverse Event Profile of Nintedanib in SSc-ILD Consistent With its Safety, Tolerability Profile in Idiopathic Pulmonary Fibrosis

Researchers characterized the safety and tolerability of nintedanib and the dose adjustments for adverse events in patients with systemic sclerosis-associated interstitial lung disease.